AZD8359 STEAP2 TCE

STEAP2-targeted T cell engager · AstraZeneca

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AZD8359 STEAP2 TCE, covering 2026-04-14 to 2026-04-14. Get the full timeline:

Most recent: Clinical Trial Update: First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer [Phase 1, Phase 2]